---
title: "001367.SZ (001367.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/001367.SZ/news.md"
symbol: "001367.SZ"
name: "001367.SZ"
parent: "https://longbridge.com/en/quote/001367.SZ.md"
datetime: "2026-03-16T02:04:46.677Z"
locales:
  - [en](https://longbridge.com/en/quote/001367.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/001367.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/001367.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/001367.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/001367.SZ/news.md)


# 001367.SZ (001367.SZ) — Related News

### [](https://longbridge.com/en/news/275062677.md)
*2026-02-06T02:37:17.000Z*
> The North Exchange 50 has increased by 1.02% within 10 days. Among the constituent stocks, Tianma New Materials rose by 

### [Haisen Pharm: Multiple executives have collectively reduced their holdings by 0.0675%, and the reduction plan has been terminated early](https://longbridge.com/en/news/271495963.md)
*2026-01-05T10:18:35.000Z*
> Haisen Pharm announced that several executives will collectively reduce their holdings by 102,900 shares through central

### [Haisen Pharm has been recognized as a national-level specialized, refined, and innovative small giant enterprise](https://longbridge.com/en/news/269690699.md)
*2025-12-15T08:53:06.000Z*
> According to the Zhitong Finance APP, Haisen Pharm announced that the company has been recognized as a "Little Giant" en

### [Some directors and senior management of Haisen Pharm plan to reduce their holdings by a total of no more than 124,300 shares](https://longbridge.com/en/news/268609827.md)
*2025-12-04T12:45:05.000Z*
> Haisen Pharm announced that some directors and senior management plan to reduce their holdings of the company's shares b

### [Haisen Pharm: Dai Ya, Zhang Shengquan, Lou Yanjun, Pan Aijuan, and Hu Kangkang plan to reduce their holdings by 0.0816%](https://longbridge.com/en/news/268602772.md)
*2025-12-04T12:10:25.000Z*
> Haisen Pharm announced that the company's director Dai Ya holds 97,680 shares (accounting for 0.0641%), and the deputy g

### [Haisen Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 88.2096 million yuan, an increase of 1.45%](https://longbridge.com/en/news/262011146.md)
*2025-10-21T08:58:03.000Z*
> Haisen Pharm released its Q3 2025 report, with operating revenue for the first three quarters at 359 million yuan, a yea

### [Haisen Pharm: Net profit of 60.7942 million yuan in the first half of 2025, a year-on-year increase of 4.74%](https://longbridge.com/en/news/253017908.md)
*2025-08-14T10:42:31.000Z*
> Haisen Pharm announced that in the first half of 2025, operating income was 242 million yuan, a year-on-year increase of

### [The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%](https://longbridge.com/en/news/251739486.md)
*2025-08-06T01:52:21.000Z*
> The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin dropping over 6%, and 

### [Haisen Pharm General Manager Ai Lin plans to reduce holdings of no more than 0.97% of shares](https://longbridge.com/en/news/242389118.md)
*2025-05-29T11:35:02.000Z*
> According to the announcement from Haisen Pharm, director and general manager Ailin, who holds 3.96% of the company's sh